Every year, US-based non-dilutive sources of funding award billions of dollars towards clinical stage research in the Life Sciences.

Funding is available for clinical stage funding across scientific fields including Infectious Diseases, Neurosciences, Cardiovascular, and many more. These funds come from multiple Institutes within the NIH, such as NIAID, NIAMS, NIDDK, from BARDA, and from the DOD.

In this webinar we discuss process for applying, guidelines, key success components and insight into increasing chances for award.

View the webinar slide deck

To discuss funding opportunities for clinical stage R&D and to learn about other non-dilutive funding that may be relevant to your organization, send us a note and we’ll get in touch with you directly!

SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone. These are excellent sources of funding aimed at promoting R&D activities of US-based small businesses as well as collaborations with Academics.

SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, diagnostics, devices, etc.

In this webinar we discuss process for applying, guidelines, key success components and insight into increasing chances for award.

View the webinar slide deck

To discuss SBIRs, STTRs, or to learn about other non-dilutive funding that may be relevant to your organization, send us a note and we’ll get in touch with you directly!

NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well.

In the upcoming webinar in the series of summer educational webinars FreeMind experts will discuss key cancer related opportunities, mainly within the National Cancer Institute (NCI), that are available for Life Science organizations.

Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical.

In the webinar in the series of summer educational webinars FreeMind experts will discuss key CNS/PNS related funding opportunities, with an emphasis on NINDS, NIA, and NIMH.

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.

The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.

In the webinar in the series of summer educational webinars FreeMind experts will discuss the latest trends at the NIH and the new available funding opportunities with respect to medical devices.

The U-Mechanism is a support mechanism used when there will be substantial Federal scientific or programmatic involvement by granting agency. Substantial involvement means that, after award, scientific or program staff will assist, guide, coordinate, or participate in project activities.

We are seeing many programs utilizing this type of mechanism, with substantial awards being made to industry as well.

In this webinar we will discuss process for applying, guidelines, key success components, and insight into increasing chances for award when pursuing U-based opportunities

Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above.

In this presentation we will provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.

The National Institute of Allergies and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA etc. this is a funding force no one in the field can afford to ignore.

Listen to FreeMind experts share insights into these tremendous sources of funding and get tips on how to maximize potential to receive an award.

Every year NIH alone awards over $120,000,000 via R’-Mechanisms, among them the RO1 or R21. In order to maximize your funding potential all sources of funding must be considered including the less traditional sources.

R21s aim to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas RO1s are more suitable for longer programs of up to 5 years, totaling some $3,000,000.

In this webinar FreeMind experts will share insight into alternatives to the classic SBIR/STTR mechanisms. We will discuss methodology for establishing both responsiveness as well as competitiveness and how to increase chances for award.

SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone to industry. These are excellent sources of funding aimed at promoting R&D activities of small businesses as well as collaborations with Academics.

SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, diagnostics, devices, etc.

In this webinar we will discuss process for applying, guidelines, key success components and insight into increasing chances for award.